



Eurofins Clinical Diagnostics continues to develop innovative solutions for transplant patient care.

Eurofins' U.S. Clinical Diagnostics Network Launches Coronavirus (COVID-19) Antibody Testing

The Eurofins' U.S. Clinical Diagnostics network announced today (April 3, 2020) that blood-based **antibody testing for Coronavirus SARS-CoV-2** will begin Monday, April 6 at Boston Heart Diagnostics, a Eurofins subsidiary. Given the overwhelming demand in acute care settings, the laboratories will initially offer the test to hospitals only. As capacity increases, and as knowledge on the disease develops, the Eurofins' network plans to begin offering testing more broadly.

Eurofins has been at the forefront of fighting SARS-CoV-2 in the U.S., launching proprietary, active infection testing through laboratories including Viracor Eurofins and Eurofins Diatherix using polymerase chain reaction (PCR) testing. Both laboratories have available capacity for additional PCR testing with same or next day results.

Unlike the NP swab-based PCR test, which are subject to the results of ongoing studies at hospitals around the world, blood-based serology testing may become a tool to identify people who were exposed, may have developed some level of immunity to COVID-19 but potentially had mild to no symptoms. Testing is recommended at least 14 days after potential exposure – giving the body the time it needs to build an immune response and produce antibodies. Over time, antibody testing is likely to become a crucial next step in fighting the spread of the virus.

Hospitals along the East Coast, including those in hot-spot areas, will have the option to courier specimens to Boston Heart Diagnostics for results in just hours. Viracor Eurofins will continue to support hospitals, transplant programs, and other immunocompromised and critically ill patients by offering its own serology test, which is expected to launch in mid-April.

The Eurofins' network will initially run nearly 5,000 tests per day, or 200 results every hour. This speed is crucial to helping first responders and healthcare providers. Over time, Eurofins' antibody testing can also help experts understand how much of the population has been infected with Coronavirus SARS-CoV-2.

Patients who suspect they were exposed to Coronavirus SARS-CoV-2 or who have experienced unconfirmed COVID-19 symptoms, should consult with a local hospital on if and how to get tested as recommended by health authorities in their state.

To order testing at Boston Heart Diagnostics, please contact customer care@bostonheartdx.com.

For questions about the testing please contact Patrick Noland at: PNoland@BostonHeartDx.com

MEDIA CONTACT:

Sloane Heller Communications

917.432.4194

sloane@sloanehellermedia.com

Announcing Labs@HOME, an In-Home Mobile Phlebotomy Blood Draw Service for Post-Transplant Patient Testing During COVID-19

Viracor Eurofins announces today the launch of Labs@HOME, a mobile phlebotomy in-home blood draw service to aid in specimen collection for vital post-transplant testing directly from a patient's home. As the hospital system becomes increasingly stressed with Coronavirus Disease 2019 (COVID-19) patients, bone marrow transplant (BMT) and solid organ transplant (SOT) patients may be unable to return to the hospital for routine and specialized post-transplant testing and management. These immunosuppressed and immunocompromised patients are already at risk for transplant rejection due to infection or graft failure, and subsequently fall into the high risk category for COVID-19.

Viracor's Labs@HOME service allows physicians to order and customize a limited menu of infectious disease and transplant-related testing. The specimen collection is performed safely and securely by a qualified phlebotomist who will work with the patient to schedule an appointment at the patient's residence. With testing tailored for BMT or SOT patients, options include key PCR tests (Adenovirus, BKV, CMV, EBV, or HHV-6), therapeutic drug monitoring for immunosuppressive and antifungal medications, CMV T Cell Immunity Panel, Viracor's TRAC™ (Transplant Rejection Allograft Check), as well as TruGraf Blood Gene Expression Test® (powered by Transplant Genomics Eurofins). The results of these tests can aid providers in making critical treatment decisions with the hope of more successful outcomes.

By providing this specialty service for the transplant community, Labs@HOME enables Viracor to help these critical patients in an integral time post-transplant in the wake of a rapidly changing healthcare situation. For more information about Labs@HOME, or to sign up to order testing through this program, contact info@viracor-eurofins.com.

Eurofins Transplant Genomics and Viracor Will Partner to Offer Remote Sample Collection Options to Support Care for Kidney Transplant Recipients During COVID-19 Outbreak

Transplant Genomics, Inc. ("TGI"), a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by genomics, today announced that it has partnered with sister Eurofins company Eurofins Viracor, and established relationships with Quest and various mobile sample collection groups, to enable patients to

have samples collected remotely for analysis with our unique catalog of tests critical to monitoring health of kidney transplant recipients without requiring them to visit transplant centers.

Key testing services include:

- **TruGraf®**: the only blood test approved by CMS for surveillance to rule out silent rejection in stable kidney transplant recipients and provide comfort that patients are likely to be immune quiescent (via Transplant Genomics)

- **Viracor TRAC™**: to analyze donor-derived cell-free-DNA levels in blood to rule out rejection in patients suspected of rejecting (via Viracor)

In addition, Eurofins - Transplant Genomics is now offering testing for SARS-CoV-2 in kidney transplant donors and recipients. Please contact us for details concerning how we can help you provide your patients with access to this important test.

Eurofins is committed to supporting physicians in providing optimal care for their transplant patients. With the outbreak of COVID-19, we understand that transplant programs are minimizing office visits, both to ensure patient health and safety, as well as reduce the burden on staff so they may focus their care on patients who are most in need. By offering our unique catalog of tests, and making available remote sample collection options, we are doing our part to support patient care during this difficult time.

For information on ordering tests and arranging remote sample collection, physicians may contact us directly at 1-844-TruGraf or (800) 305-5198 for Eurofins Viracor Client Services. You may also visit our websites at www.trugraf.com, Viracor-Eurofins.com/TRAC and Viracor-Eurofins.com/Coronavirus.

The National Kidney Registry and Viracor Eurofins Announce Coronavirus COVID-19 Rapid Turnaround Transplant Testing for Donors and Recipients

The National Kidney Registry (NKR) and Viracor Eurofins announced a partnership today to deliver testing for Coronavirus SARS-CoV-2 (the virus that causes COVID-19 disease) to NKR's vast network of Member Centers. NKR is the largest paired exchange program in the world and serves approximately 100 transplant programs throughout the United States. NKR has relied on Eurofins' specialty transplantation laboratories, VRL Eurofins and Viracor Eurofins, for over seven years to process mission critical tests to support NKR's paired exchange operation. Viracor announced availability of its COVID-19 assay on March 13th following validation in accordance with the FDA Emergency Use Authorization Guidance.

"We are pleased to announce that thousands of COVID-19 test kits will arrive at NKR Member Centers by Thursday March 19th. These test kits can be used to test living donors, recipients of living donor organs and recipients of deceased donor organs. Our goal is to increase transplant safety for donors and recipients during this challenging time," said Gareth Hil, Founder and CEO, National Kidney Registry. "We are grateful for the rapid response from Eurofins in

developing this solution and we are indebted to key members of our Medical Board for guiding us through this process. We are especially grateful to Dr. Robert Redfield at UW Madison for quickly overcoming a serious regulatory obstacle that had the potential to stop the roll-out of this solution."

Viracor Eurofins is thrilled to be working with NKR and believe that by combining resources we can play a pivotal role in helping transplant programs reduce COVID-19 risk for their donors and patients. Given the concerns surrounding COVID-19, particularly within immunosuppressed populations, like transplant recipients, we are pleased to support the transplant community as we work through this current healthcare challenge.

About the National Kidney Registry

The National Kidney Registry (www.kidneyregistry.org) is a nonprofit organization with the mission to save and improve the lives of people facing kidney failure by protecting living donors and increasing the quality, speed, and number of living donor transplants.

About Boston Heart Diagnostics

Boston Heart Diagnostics of Framingham, MA has been a leader in advanced cardiovascular testing for the past 14 years, and became part of the Eurofins laboratory network about 5 years ago. The company is committed to providing medical professionals throughout the country with specialized biochemical and genetic testing so that can optimize lifestyle modification and medication in their patients for cardiovascular disease (CVD) prevention. Because CVD patients are at substantially higher risk of mortality from Coronavirus SARS-CoV-2 infection, Boston Heart Diagnostics is pleased to be able to offer both nasal-pharyngeal swab and IgM and IgG antibody testing as of April 6th, 2020. For more information, please visit <https://www.bostonheartdiagnostics.com>.

About Eurofins - A global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agriscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialized by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the

latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

About Transplant Genomics Inc.

Transplant Genomics, Inc. ("TGI") is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immune-suppressive therapy, enhance patient care and improve graft survival. Test services are offered through TGI's CLIA laboratory in Pleasanton, CA. TGI was acquired by Eurofins in 2019.

About Viracor Eurofins

With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories and biopharmaceutical companies get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves.

Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit <https://www.eurofins.com/> and <https://www.viracor-eurofins.com/> .